
Supplementary Materials:

Dereplication by High-Performance Liquid Chromatography (HPLC) with Quadrupole-Time-of-Flight Mass Spectroscopy (qTOF-MS) and Antiviral Activities of Phlorotannins from *Ecklonia cava*

Hyo Moon Cho ^{1,†}, Thi Phuong Doan ^{1,†}, Thi Kim Quy Ha ¹, Hyun Woo Kim ¹, Ba Wool

Lee ¹, Ha Thanh Tung Pham ¹, Tae Oh Cho ² and Won Keun Oh ^{1,*}

¹ Korea Bioactive Natural Material Bank, Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Korea; chgyans@naver.com (H.M.C.); phuongdoan@snu.ac.kr (T.P.D.); htkquy@ctu.edu.vn (T.K.Q.H.); kimkami2@snu.ac.kr (H.W.K.); paul36@snu.ac.kr (B.W.L.); thtungdl@gmail.com (H.T.T.P.)

² Marine Bio Research Center, Department of Life Science, Chosun University, Gwangju 501-759, Korea; tocho@chosun.ac.kr

* Correspondence: wkoh1@snu.ac.kr; Tel.: +82-02-880-7872


† These authors contributed equally.

Contents

17		
18	Figure S1. HRESIMS spectrum of compound 1	Error! Bookmark not defined.
19	Figure S2. IR spectrum of compound 1	5
20	Figure S3. ^1H NMR spectrum of compound 1 (800 MHz, $\text{DMSO-}d_6$).....	6
21	Figure S4. ^{13}C NMR spectrum of compound 1 (200 MHz, $\text{DMSO-}d_6$).....	Error! Bookmark
22	not defined.	
23	Figure S5. HSQC spectrum of compound 1 (800 MHz, $\text{DMSO-}d_6$).....	Error! Bookmark not
24	defined.	
25	Figure S6. HMBC spectrum of compound 1 (800 MHz, $\text{DMSO-}d_6$)	10
26	Figure S7. ROESY spectrum of compound 1 (800 MHz, $\text{DMSO-}d_6$).....	Error! Bookmark
27	not defined.	
28	Figure S8. HRESIMS spectrum of compound 2	11
29	Figure S9. IR spectrum of compound 2	12
30	Figure S10. ^1H NMR spectrum of compound 2 (850 MHz, $\text{DMSO-}d_6$).....	13
31	Figure S11. ^{13}C NMR spectrum of compound 2 (212.5 MHz, $\text{DMSO-}d_6$).....	14
32	Figure S12. HSQC spectrum of compound 2 (850 MHz, $\text{DMSO-}d_6$)	15
33	Figure S13. HMBC spectrum of compound 2 (850 MHz, $\text{DMSO-}d_6$)	16
34	Figure S14. ROESY spectrum of compound 2 (850 MHz, $\text{DMSO-}d_6$).....	17

35	Figure S15. Relationships between ion masses (m/z value) in negative ion mode and RMD	
36	values for compounds detected by HPLC-qTOFMS in the EC70 fraction	18
37	Figure S16. HPLC-qTOFMS measurement for twelve isolated compounds in negative ion	
38	mode at collision energy of 50 eV	19
39	Figure S17. MS/MS spectra and fragment ions analysis of isolated compounds. HPLC-	
40	qTOFMS spectroscopic data of these single compounds were measured in negative mode	
41	at collision energy of 50 eV.....	20
42	Figure S18. Effects of compound 11 , 12 , 13 , and 14 on the viral protein synthesis at a	
43	concentration of 20 μ M; original uncropped blots	21
44	Figure S19. Inhibitory effects of compound 12 on the viral proteins synthesis in a	
45	concentration-dependent manner; original uncropped blots.....	22-23
46	Figure S20. (A) Key HMBC correlations of compounds 1 and 2 . (B) Key ROESY	
47	correlations on 3D structure of compounds 1 and 2	24
48	Figure S21. Physicochemical properties of isolated known compounds from <i>E. cava</i> .	25-28
49	Table S1. List of species in <i>Ecklonia</i> genus from website World Register of Marine Species	
50	(http://www.marinespecies.org).....	29
51	Table S2. The inhibitory effects of compounds 11 , 12 , 13 , and 14 against the H1N1	
52	A/PR/8/34 virus in a cytopathic effect and cytotoxicity assays.....	30
53	Table S3. ^1H and ^{13}C NMR spectroscopic data of compounds 1 and 2 in DMSO- d_6 (δ in	
54	ppm)	31
55	Scheme S1. Extraction and fractionation procedure of <i>E. cava</i>	32
56		


57 Figure S1. HRESIMS spectrum of compound 1.



58 --- End Of Report ---

59 **Figure S2.** IR spectrum of compound **1**.

60



[Comment]
 Sample Name
 Comment
 User
 Division
 Company 공 동 기 기 실

[Measurement Information]
 Model Name FT/IR-4200typeA
 Serial Number B038361018

EC2-3.2


Light Source Standard
 Detector TGS
 Accumulation 16
 Resolution 4 cm⁻¹
 Zero Filling On
 Apodization Cosine
 Gain Auto (2)
 Aperture Auto (7.1 mm)
 Scanning Speed Auto (2 mm/sec)
 Filter Auto (30000 Hz)

[Data Information]
 Creation Date 2018-10-26 오전 11:20
 Data array type Linear data array
 Horizontal Wavenumber [cm⁻¹]
 Vertical %T
 Start 599.753 cm⁻¹
 End 4000.6 cm⁻¹
 Data pitch 0.964233 cm⁻¹
 Data points 3528

61

62


63 **Figure S3.** ^1H NMR spectrum of compound **1** (800 MHz, $\text{DMSO-}d_6$).



64

65


66 **Figure S4.** ^{13}C NMR spectrum of compound **1** (200 MHz, $\text{DMSO}-d_6$).



67


68

69 **Figure S5.** HSQC spectrum of compound **1** (800 MHz, DMSO- d_6).



71 **Figure S6.** HMBC spectrum of compound **1** (800 MHz, DMSO- d_6).


72



73

74

75 **Figure S7.** ROESY spectrum of compound **1** (800 MHz, DMSO- d_6).



77 Figure S8. HRESIMS spectrum of compound 2.


Qualitative Compound Report

Data File	EC2-3-2-6_5.d	Sample Name	EC2-3-2-6
Sample Type	Sample	Position	p1f1
Instrument Name	Instrument 1	User Name	6530-PC\admin
Acq Method	DIP method-Op.m	Acquired Time	11/8/2018 9:50:42 AM
IRM Calibration Status	Success	DA Method	Default.m
Comment			
Sample Group	Info.		
Stream Name	LC 1		


Compound Table

Compound Label	RT	Mass	Abund	Formula	Tgt Mass	Diff (ppm)
Cpd 1: C54H34O27	0.166	1114.1285	41944	C54H34O27	1114.1287	-0.18

Compound Label	RT	Algorithm	Mass
Cpd 1: C54H34O27	0.166	Find By Formula	1114.1285



MS Spectrum




MS Spectrum Peak List

m/z	Calc m/z	Diff(ppm)	z	Abund	Formula	Ion
557.0617	557.0649	-5.71	-2	3347	C54 H34 O27	M-2
1095.0915	1095.1109	-17.76	-1	569	C54 H31 O26	(M-H)-[-H2O]
1096.1575	1096.1187	35.38	-1	248	C54 H32 O26	M*-[-H2O]
1113.1215	1113.1215	0.01		41944	C54 H33 O27	(M-H)-
1114.1237	1114.1249	-1.04		25939	C54 H33 O27	(M-H)-
1115.129	1115.1276	1.26		10241	C54 H33 O27	(M-H)-
1131.1	1131.0876	10.99	-1	60	C54 H32 Cl O26	(M+Cl)-[-H2O]
1141.1303	1141.1164	12.2	-1	302	C55 H33 O28	(M+HCOO)-[-H2O]
1149.1163	1149.0981	15.77	-1	624	C54 H34 Cl O27	(M+Cl)-
1159.1174	1159.1269	-8.28	-1	407	C55 H35 O29	(M+HCOO)-

79 **Figure S9.** IR spectrum of compound 2.

80



[Comment]
Sample Name
Comment
User
Division
Company

공동기기실

[Data Information]

Creation Date 2018-10-26 오전 11:10
Data array type Linear data array
Horizontal Wavenumber [cm⁻¹]
Vertical %T
Start 599.753 cm⁻¹
End 4000.6 cm⁻¹
Data pitch 0.964233 cm⁻¹
Data points 3528

[Measurement Information]


Model Name FT/IR-4200typeA
Serial Number B038361018

Light Source Standard
Detector TGS
Accumulation 16
Resolution 4 cm⁻¹
Zero Filling On
Apodization Cosine
Gain Auto (2)
Aperture Auto (7.1 mm)
Scanning Speed Auto (2 mm/sec)
Filter Auto (30000 Hz)


EC2-3.2.6

81


82 **Figure S10.** ^1H NMR spectrum of compound **2** (850 MHz, $\text{DMSO-}d_6$).




84 **Figure S11.** ^{13}C NMR spectrum of compound **2** (212.5 MHz, $\text{DMSO-}d_6$).




86 **Figure S12.** HSQC spectrum of compound **2** (850 MHz, DMSO- d_6).




88 **Figure S13.** HMBC spectrum of compound **2** (850 MHz, DMSO- d_6).



90 **Figure S14.** ROESY spectrum of compound **2** (850 MHz, DMSO- d_6).



92 **Figure S15.** Relationships between ion masses (m/z value) in negative ion mode and RMD values for compounds detected by HPLC-qTOFMS in
93 the EC70 fraction.



96 **Figure S16.** HPLC-qTOFMS measurement of twelve isolated compounds in negative ion
97 mode at collision energy of 50 eV.




Figure S17. MS/MS spectra and fragment ions analysis of isolated compounds. HPLC-qTOFMS spectroscopic data of these single compounds were measured in negative mode at collision energy of 50 eV.




Figure S18. Effects of compound **11**, **12**, **13**, and **14** on the viral protein synthesis at a concentration of 20 μ M; original uncropped blots.

The viral-infected cells were exposed to compounds **11**, **12**, **13**, and **14** (20 μ M) and ribavirin (20 μ M) as a positive control. After 1 day of incubation, the cell lysates were collected and target proteins were measured using Western blotting method. Equal amounts of proteins were loaded on SDS-polyacrylamide gels. After transferred to PVDF membranes, they were firstly incubated with neuraminidase antibody overnight. For removing bound primary and secondary antibodies, the membranes were incubated with a RestoreTM Western blot stripping buffer (Thermo Sci.) and they were then detected the β -actin protein using a LAS4000 luminescent image analyzer. Sample names were from 1-7 as follows: uninfected ctrl, viral-infected (vi) ctrl, vi + ribavirin (20 μ M), vi + **11**, **12**, **13**, and **14** (20 μ M), respectively. Data were included in the final analysis in Figure 4A.







Figure S179. Inhibitory effects of compound **12** on the viral proteins synthesis in a concentration-dependent manner; original uncropped blots.

The procedure of Western blot experiment was successfully carried as above described in Figure S18. The membranes were firstly detected neuraminidase or hemagglutinin proteins. Using a stripping buffer (Thermo Sci.) for removing bound primary and secondary antibodies, the membranes were then incubated with β -actin antibody. (A) Sample names were from 1-7 as follows: uninfected ctrl, viral-infected (vi) ctrl, vi + ribavirin (20 μ M), vi + **12** (5, 10, 20, and 40 μ M), respectively. (B) Sample names were from 1-6 as follows: uninfected ctrl, vi ctrl, vi + ribavirin (20 μ M), vi + **12** (5, 10, and 20 μ M), respectively. (C) Sample names were from 1-12 as follows: uninfected ctrl-1; vi ctrl-1; vi + ribavirin (20 μ M)-1, -2; vi + **12** (10 μ M)-1, -2; vi + **12** (20 μ M)-1, -2; vi + **12** (40 μ M)-1, -2; vi ctrl-2; uninfected ctrl-2; respectively. Figure 4B was included in the final analysis.





137 **Figure S20.** (A) Key HMBC correlations of compounds **1** and **2**. (B) Key ROESY
 138 correlations on 3D structure of compounds **1** and **2**.




Figure S21. Physicochemical properties of isolated known compounds from *E. cava*.

Eckol (6)

Brown powder; UV (MeOH) λ_{max} nm (log ϵ) 210 (2.70), 235 (2.75); ESI-MS m/z 371 [M – H][–]; ¹H NMR (DMSO-*d*₆, 300 MHz): δ 6.16 (1H, s, H-3), 5.97 (1H, d, J = 2.4 Hz, H-8), 5.80 (1H, d, J = 2.4 Hz, H-6), 5.79 (1H, t, J = 2.4 Hz, H-4'), 5.71 (2H, d, J = 2.1 Hz, H-2', H-6'); ¹³C NMR (DMSO-*d*₆, 75 MHz): δ 160.3 (C-1'), 158.8 (C-3', C-5'), 153.0 (C-7), 146.1 (C-9), 146.0 (C-2), 142.5 (C-5a), 141.9 (C-4), 137.1 (C-10a), 123.1 (C-1), 122.5 (C-9a), 122.0 (C-4a), 98.4 (C-8), 98.1 (C-3), 96.2 (C-4'), 93.7 (C-6), 93.6 (C-2', C-6').

7-Phloroeckol (7)

Brown powder; UV (MeOH) λ_{max} nm (log ϵ) 210 (2.34), 230 (2.27); ESI-MS m/z 495 [M – H][–]; ¹H NMR (DMSO-*d*₆, 300 MHz): δ 6.14 (s, H-3), 6.00 (1H, d, J = 2.9, H-8), 5.77 (1H, d, J = 2.9, H-6), 5.80 (1H, d, J = 1.9 Hz, H-4'), 5.86 (1H, d, J = 2.4 Hz, H-2', H-6'); ¹³C NMR (DMSO-*d*₆, 75 MHz): δ 122.2 (C-1), 146.0 (C-2), 98.4 (C-3), 141.9 (C-4), 123.2 (C-4a), 142.9 (C-5a), 93.4 (C-6), 154.6 (C-7), 98.1 (C-8), 146.1 (C-9), 124.0 (C-9a), 137.1 (C-10a), 160.3 (C-1'), 93.6 (C-2'), 159.0 (C-3'), 96.3 (C-4'), 159.0 (C-5'), 93.7 (C-6'), 122.9 (C-1''), 151.3 (C-2''), 94.9 (C-3''), 154.9 (C-4''), 94.9 (C-5''), 151.3 (C-6'')

6,6'-Bieckol (10)

Brown powder; UV (MeOH) λ_{max} nm (log ϵ) 210 (2.34), 230 (2.27); ESI-MS m/z 743 [M + H]⁺, 741 [M – H][–]; ¹H NMR (DMSO-*d*₆, 300 MHz): δ 6.09 (s, H-3), 6.04 (1H, s, H-8), 5.80 (1H, d, J = 1.8 Hz, H-4'), 5.74 (1H, d, J = 2.1 Hz, H-2', H-6'); ¹³C NMR (DMSO-*d*₆, 75 MHz): δ 160.5 (C-1'), 158.9 (C-3', C-5), 151.3 (C-7), 145.4 (C-2), 144.5 (C-9), 141.9 (C-

168 4), 141.4 (C-5a), 137.2. (C-10), 123.6 (C-1), 122.7 (C-9a), 122.0 (C-4a), 99.7 (C-6), 97.8
 169 (C-8), 97.8 (C-3), 96.2 (C-4'), 93.7 (C-2', C-6').

170

171 Dieckol (**11**)

172 Brown powder; UV (MeOH) $\lambda_{\max}$ nm (log ϵ) 210 (2.70), 235 (2.75); ESI-MS m/z 743 [M +
 173 H]⁺, 741 [M – H][–]; ¹H NMR (DMSO-*d*₆, 300 MHz): δ 6.16 (1H, s, H-1"), 6.14 (1H, s, H-
 174 3), 6.01 (1H, d, J = 2.2 Hz, H-8), 6.99 (1H, d, J = 2.2 Hz, H-8"), 5.94 (1H, s, H-2"', H-6'''),
 175 5.82 (1H, br d, J = 2.7 Hz, H-6), 5.81 (1H, br d, J = 2.8 Hz, H-6"), 5.79 (1H, t-like, H-4'),
 176 5.71 (1H, br d, H-2', H-6'); ¹³C NMR (DMSO-*d*₆, 75 MHz): δ 160.3 (C-1'), 158.8 (C-2', C-
 177 5'), 155.9 (C-1'''), 154.2 (C-7), 153.1 (C-7"), 151.2 (C-3''', C-5'''), 146.1 (C-2), 146.1 (C-
 178 9"), 146.0 (C-9), 145.9 (C-2"), 142.6 (C-5a"), 142.4 (C-5a), 142.0 (C-4"), 141.9 (C-4),
 179 137.2 (C-10a), 137.0 (C-10a"), 124.2 (C-1"), 124.0 (C-9a), 123.2 (C-4a") 123.1 (C-4),
 180 122.5 (C-9a"), 122.2 (C-1"), 122.1 (C-1).

181

182 Phlorofucofuroeckol A (**12**)

183 Brown powder; UV (MeOH) $\lambda_{\max}$ nm (log ϵ) 210 (3.17), 225 (3.16); ESI-MS m/z 601 [M –
 184 H][–]; ¹H NMR (DMSO-*d*₆, 300 MHz): δ 6.72 (1H, s, H-13), 6.43 (1H, s, H-9), 6.30 (1H, s,
 185 H-3), 5.83 (2H, br t, J = 1.6 Hz, H-4', H-4''), 5.76 (2H, d, J = 2.0 Hz, H-2', H-6'), 5.72 (2H,
 186 d, J = 2.0 Hz, H-2', H-6'); ¹³C NMR (DMSO-*d*₆, 75 MHz): δ 160.2 (C-1'), 160.0 (C-1''),
 187 159.0 (C-3'', C-5''), 158.9 (C-3', C-5'), 150.8 (C-12a), 150.4 (C-10), 149.5 (C-11a), 147.0
 188 (C-2), 146.5 (C-8), 144.8 (C-14), 142.1 (C-4), 136.8 (C-15a), 134.0 (C-5a), 126.3 (C-14a),
 189 122.5 (C-1), 122.4 (C-4a), 120.1 (C-11), 103.4 (C-7), 103.2 (C-6), 99.1 (C-9), 98.3 (C-3),
 190 96.3 (C-4, C-4''), 94.8 (C-13), 93.7 (C-2', C-6'), 93.5 (C-2'', C-6'').

191

192 Dibenzo [1,4]dioxine-2,4,7,9-tetraol (**13**)

193 Brown powder; UV (MeOH) $\lambda_{\max}$ nm (log ε) 228 (1.59), 278 (0.79); ESI-MS m/z 247 [M –
 194 H][–]; ¹H NMR (DMSO-*d*₆, 300 MHz): δ 5.96 (2H, d, J = 2.7 Hz, H-3, H-8), 5.78 (2H, d, J =
 195 2.7 Hz, H-1, H-6); ¹³C-NMR (DMSO-*d*₆, 75 MHz): δ 152.8 (C-2, C-7), 145.8 (C-4, C-9),
 196 142.8 (C-5a, C-10), 122.9 (C-4a C-9a), 98.3 (C-3, C-8), 93.9 (C-1, C-6).

197

198 Dioxinodehydroeckol (**14**)

199 Brown powder; UV (MeOH) $\lambda_{\max}$ nm (log ε) 235 (2.85); ESI-MS m/z 369 [M – H][–]; ¹H
 200 NMR (DMSO-*d*₆, 300 MHz): δ 6.10 (1H, s, H-7), 6.05 (1H, d, J = 2.7 Hz, H-2), 6.02 (1H,
 201 d, J = 2.7 Hz, H-10), 5.84 (1H, d, J = 2.7 Hz, H-4), 5.82 (1H, d, J = 2.7 Hz, H-12); ¹³C
 202 NMR (DMSO-*d*₆, 75 MHz): δ 153.3 (C-3), 153.0 (C-11), 146.1 (C-1), 145.9 (C-9), 142.0
 203 (C-4a), 141.7 (C-12a), 140.1 (C-6), 137.1 (C-7a), 131.5 (C-13b), 122.6 (C-8), 122.5 (C-
 204 13a), 122.2 (C-14a), 98.8 (C-2, C-10), 97.9 (C-7), 93.9 (C-4, C-12).

205

206 6,8'-Bieckol (**15**)

207 Brown powder; UV (MeOH) $\lambda_{\max}$ nm (log ε) 210 (2.34), 230 (2.27); ESI-MS m/z 743 [M +
 208 H]⁺, 741 [M – H][–]; ¹H NMR (DMSO-*d*₆, 300 MHz): δ 6.13 (1H, s, H-8), 6.03 (1H, s, H-3'),
 209 6.00 (1H, s, H-3), 5.92 (1H, s, H-6'), 5.75 (2H, t, J = 1.6 Hz, H-4'', H-4'''), 5.71 (2H, d, J =
 210 2.4 Hz, H-2'', H-6''), 5.68 (2H, J = 1.6 Hz, H-2'', H-6''); ¹³C NMR (DMSO-*d*₆, 75 MHz): δ
 211 160.0(C-1'', C-1'''), 158.0 (C-3'', C-5'''), 158.0 (C-3'', C-5''), 151.5 (C-7, C-7'), 145.8 (C-2),
 212 145.5 (C-2'), 144.9 (C-9), 144.4 (C-9'), 141.9 (C-4), 141.4 (C-4'), 141.7 (C-5a), 140.0 (C-
 213 5a'), 137.3 (C-10a), 137.2 (C-10a'), 123.6 (C-1), 123.4 (C-1'), 123.0 (C-9a), 122.9 (C-9a'),
 214 122.4 (C-4a), 122.0 (C-4a'), 104.5 (C-8'), 99.5 (C-6), 98.2 (C-8), 97.0 (C-3), 97.0 (C-3'),
 215 96.3 (C-4''), 93.9 (C-2''', C-6'''), 93.8 (C-2'', C-6''), 93.7 (C-6').

216

217 Fucofuroeckol A (**16**)

218 Brown powder; UV (MeOH) λ_{max} nm (log ϵ) 208 (2.10), 224 (2.33), 300 (1.63); ESI-MS
 219 m/z 477 $[M - H]^-$; ^1H NMR (DMSO- d_6 , 300 MHz) δ 6.72 (1H, s), 6.47 (1H, s), 6.29 (1H,
 220 s), 6.25 (1H, d, $J = 1.8$ Hz, H-9), 5.83 (1H, t, $J = 2.1$ Hz, H-4'), 5.76 (2H, d, $J = 2.1$ Hz, H-
 221 2', H-6')
 222
 223 974-A (**18**)
 224 Brown powder; UV (MeOH) λ_{max} nm (log ϵ) 208 (2.10), 224 (2.33), 300 (1.63); ESI-MS
 225 m/z 973 $[M - H]^-$; ^1H NMR (DMSO- d_6 , 300 MHz) δ 6.15 (1H, d, $J = 2.1$ Hz, H-4'), 6.01
 226 (1H, d, $J = 2.1$ Hz, H-6'), 6.26 (1H, s, H-3), 6.72 (1H, s, H-6), 6.44 (1H, s, H-10), 6.73 (2H,
 227 d, $J = 1.8$ Hz, H-2'', H-6''), 5.83 (1H, dt, $J = 1.8, 2.1$ Hz, H-4''), 6.11 (1H, d, $J = 1.2$ Hz,
 228 H4'''), 5.75 (1H, d, $J = 1.5$ Hz, H-6'''), 5.86 (2H, s, H-3''', H-5''') ; ^{13}C -NMR (DMSO- d_6 ,
 229 75 MHz): δ 157.9 (C-1'), 120.1 (C-2'), 157.7 (C-3'), 99.2 (C-4'), 158.8 (C-5'), 95.9 (C-6'),
 230 136.9 (C-1), 146.6 (C-2), 103.4 (C-3), 146.1 (C-4), 141.9 (C-4a), 142.4 (C-15a), 145.9 (C-
 231 5a), 92.7 (C-6), 153.1 (C-6), 153.1 (C-6a), 123.5 (C-13), 123.5 (C-13), 144.7 (C-14), 142.0
 232 (C-14a), 150.1 (C-7a), 126.4 (C-8), 150.4 (C-9), 103.3 (C-10), 149.6 (C-11), 122.9 (C-12),
 233 160.3 (C-1''), 96.5 (C-2'', C-6''), 160.0 (C-3'', C-5''), 98.4 (C-4''), 158.1 (C-1'''), 122.1 (C-
 234 2'''), 157.8 (C-3'''), 100.7 (C-4'''), 159.0 (C-5'''), 94.9 (C-6'''), 137.1 (C-1'''), 151.3 (C-2'''),
 235 97.5 (C-3'''), 155.8 (C-4'''), 93.6 (C-5'''), 154.7 (C-6'''), 133.9 (C-1'''), 150.9 (C-2'''), C-
 236 6'''), 96.9 (C-3''', C-5'''), 154.8 (C-4''').

237 **Table S1.** List of species in *Ecklonia* genus from website World Register of Marine Species (<http://www.marinespecies.org>).

No	Species	Other name	Distribution
1	<i>Ecklonia bicyclis</i>	<i>Eisenia bicyclis</i> <i>Ecklonia wrightii</i>	Pacific Ocean waters (Japan, Korea)
2	<i>Ecklonia biruncinata</i>	<i>Ecklonia exasperata</i> , <i>Ecklonia radiata</i>	Indian Ocean (Australia, Madagascar, Oman, South Africa)
3	<i>Ecklonia brevipes</i>		Australia, New Zealand
4	<i>Ecklonia buccinalis</i>	<i>Ecklonia maxima</i>	South Africa
5	<i>Ecklonia caepaestipes</i>	<i>Durvillaea antarctica</i>	New Zealand
6	<i>Ecklonia cava</i>	<i>Ecklonia latifolia</i>	Japan, Korea
7	<i>Ecklonia fastigiata</i>		South Africa
8	<i>Ecklonia kurome</i>		Japan
9	<i>Ecklonia muratii</i>		Northern hemisphere (Mauritania, Senegal)
10	<i>Ecklonia radicata</i>	<i>Eckloniopsis radicata</i>	Japan
11	<i>Ecklonia richardiana</i>		New Zealand
12	<i>Ecklonia stolonifera</i>		Japan, Korea

238

239

240

241

242

243

244

Table S2. The inhibitory effects of compounds **11**, **12**, **13** and **14** against the H1N1 A/PR/8/34 virus in a cytopathic effect and cytotoxicity assays.

Comp. No	EC ₅₀ (μM)	CC ₅₀ (μM)
11	17.34 ± 3.97	> 100
12	13.48 ± 1.93	> 100
13	23.95 ± 2.00	> 100
14	23.41 ± 4.72	> 100
Ribavirin	4.29 ± 1.30	-

EC₅₀: Effective concentration; CC₅₀: Cytotoxic concentration

258 **Table S3.** ^1H and ^{13}C NMR spectroscopic data of compounds **1** and **2** in DMSO- d_6 (δ in
259 ppm).


Ring	1 ^a			2 ^b		
	No.	δ_{H_i} (Mult. / in Hz)	δ_c	No.	δ_{H_i} (Mult. / in Hz)	δ_c
A	1		122.6	1'		160.1
	2		144.7	2', 6'	5.74 (2H, d, 1.8)	93.7
	3	6.12 (1H, s, overlap)	98.1	3', 5'		158.9
	4		142.2	4'	5.81 (1H, brt)	96.4
	4a		123.3			
	10a		137.2			
B	5a		142.4	1		123.7
	6	5.81 (1H, d, 2.7)	93.7	2		145.8
	7		153.1	3	5.92 (1H, s)	95.8
	8	5.97 (1H, d, 2.7)	98.5	4		143.1
	9		146.1	4a		123.8
	9a		122.6	10a		137.2
	OH-7	9.11 (1H, brs)				
C	1'		157.9	5a		142.3
	2'	5.99 (1H, d, 1.5)	94.7	6	5.88 (1H, d, 2.2)	93.9
	3'		157.7	7		153.2
	4'		100.7	8	6.01 (1H, d, 2.2)	98.7
	5'		158.1	9		146.2
	6'	6.09(1H, brs)	96.8	9a		122.5
D	1''		101.4	1''		122.1
	2''		155.7	2'', 6''		151.3
	3''	5.70 (1H, d, 1.5)	93.8	3'', 5''	5.87 (2H, s)	94.9
	4'', 6''		157.7	4''		154.7
	5''	6.12 (1H, s, overlap)	97.3			
	OH-4''	8.88 91H, brs)				
	OH-6''	9.19 (1H, brs)				
E	1'''		123.5	1'''		123.5
	2'''		150.0	2'''		150.1
	3'''	5.54 (1H, d, 2.7)	92.7	3'''	5.55 (1H, d, 2.4)	92.7
	4'''		153.1	4'''		153.1
	5'''	5.89 (1H, d, 2.7)	95.8	5'''	5.89 (1H, d, 2.4)	95.9
	6'''		154.7	6'''		154.8
	OH-4''', 6'''	8.98 (2H, brs)				
F	1''''		122.1	1''''		101.5
	2''', 6''''		151.2	2''''		157.9
	3''', 5''''	5.86 (2H, s)	94.9	3''''	5.71 (1H, brs)	93.5
	4''''		154.7	4''''		157.8
	OH-4''''	8.89 (1H, brs)		5''''	6.14 (1H, brs)	97.5
	OH-6''''	9.05 (1H, brs)		6''''		155.7
G				1'''''		100.7
				2'''''		
				3'''''	6.00 (1H, brs)	94.9
				4'''''		157.8
				5'''''	6.11 (1H, brs)	96.8
				6'''''		
H				1''''''		121.4
				2''''''		136.7
				3''''''		122.9
				4''''''		142.6
				5''''''	6.21 (1H, s)	98.4
				6''''''		145.9
I				1'''''''		
				2'''''''		
				3'''''''		
				4'''''''	6.14 (1H, s)	98.3
				5'''''''		
				6'''''''		

^a measured in 800 MHz, ^b measured in 850 MHz

260

261 **Scheme S1.** Extraction and fractionation of *E. Cava*.

262



263